Paris, France, January 4, 2023, 7:30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate in the following investor conferences in January 2023:
26th ODDO BHF Forum
January 9 – 10, 2023 – Virtual
Bernard Gilly, Co-Founder & Chief Executive Officer, and Thomas Gidoin, Chief Financial Officer, will host investor meetings.
Invest Securities Biomed Forum
January 24, 2023 – Paris, France
Thomas Gidoin, Chief Financial Officer, will attend in person and host investor meetings.
11th Degroof Petercam Healthcare Conference
January 25, 2023 – Virtual
Thomas Gidoin, Chief Financial Officer, will host investor meetings.
GenSight BiologicsCorporate Communications DirectorClothilde Caillet
Rooney PartnersMedia RelationsJeanene Timberlake+1 646-770-8858
LifeSci AdvisorsInvestor RelationsGuillaume van Renterghem+41 (0)76 735 01 31
Orpheon FinanceRetail InvestorsJames Palmer+33 7 60 92 77 74